8. Health economics and clinical trials

Colin Green, PhD, Health Economics Group, University of Exeter, UK.

P102: Cost of illness and economic burden of early Alzheimer’s disease: a systematic review
Richard Lawson, MSc\(^1\), Weiguang Xue, MSc\(^2\), Adam Lloyd, MPhil\(^2\), Christina-Jane Crossman-Barnes, MSc\(^3\), Rebekah Fong, MSc\(^1\)
(1) AstraZeneca, US (2) QuintilesIMS, UK (3) University of East Anglia, UK

P103: Challenges in Optimising Real World Evidence for Alzheimer’s Disease
Catherine Reed, PhD, Frederic de Reydet de Vulpillieres, MSc\(^2\), John Gallacher, PhD\(^3\), and the ROADMAP consortium
(1) Eli Lilly and Company Limited, Windlesham, UK (2) Novartis Pharma AG, Basel, Switzerland (3) University of Oxford, UK

P104: Dependence Scale to Assess the Cost-Consequences of Alzheimer’s Disease Treatments
Joshua A. Roth, PhD, MHA\(^1\), Joshua T. Cohen, PhD\(^2\), Peter J. Neumann, ScD\(^2\), Carolyn W. Zhu, PhD\(^3\), Yaakov Stern, PhD\(^4\), Sean D. Sullivan, PhD\(^5\)
(1) Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA (2) Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA (3) Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA (4) Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA (5) Department of Pharmacy, University of Washington, Seattle, WA, USA